Avirmax's Chief Executive and Scientific Officer, Dr. Shengjiang Shawn Liu, Ph.D., will chair the upcoming session of " Acceleration of AAV Gene Therapy for Ocular Diseases: Improving Delivery and ...
Carlos Quezada-Ruiz, M.D., FASRS, SVP, Therapeutic Area Head, Ophthalmology ...
Ascend Advanced Therapies, which has been on an expansion tear since debuting three years ago, inked a deal with EW ...
The multicenter Phase1b open-label dose escalation study (NCT05973630) will evaluate safety, pharmacodynamics, efficacy, and immunogenicity in children receiving intravenous ATA-200, a single-dose ...
Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm’s clinical program is a LVV-based gene therapy for ...
MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, ...
Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent ...
Ascend’s fill/finish capacity in the US will also be expanded. “We founded Ascend with a vision to quilt together the best operators and technologies within the advanced manufacturing field. The ...
Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is ...
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using ...
Analysts did not seem very concerned by the treatment-related serious adverse event, noting that NGN-401 was well-tolerated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback